参考文献/References:
1 于莉. 骨代谢标志物实验室检测在绝经后骨质疏松症治疗中的意义 [J]. 风湿病与关节炎, 2015, 4(2): 18-21.
2 刘忠厚. 骨质疏松诊断 [M] . 香港: 中国现代文艺出版社, 2011: 595-610.
3 Sambrook P, Cooper C. Osteoporosis [J]. Lancet, 2006, 367(9527): 2010-2018.
4 阙文君, 冯正平 (审校). 骨转换生化标志物的研究进展 [J]. 中国骨质疏松杂志, 2014, 20(5): 575-579.
5 Hannon RA, Clowes JA, Eagleton AC, et al. Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption [J]. Bone, 2004, 34(1): 187-194.
6 张新菊, 李融. 骨代谢标志物相关研究进展 [J]. 山东医药, 2014, 54(16): 93-95.
7 Mukaiyama K, Kamimura M, Uchiyama S, et al. Elevation of serum alkaline phosphatase (ALP) level in postmenopausal women is caused by high bone turnover [J]. Aging Clin Exp Res, 2015, 27(4): 413-418.
8 徐献明. 骨转换的生化指标应用进展 [J]. 重庆医学, 2012, 41(15): 1502-1504.
9 Jurutka PW, Macdonald PN, Nakajima S, et al. Isolation of baculovirus-expressed human vitamin D receptor: DNA responsive element interactions and phosphorylation of the purified receptor [J]. J Cell Biochem, 2002, 85(2): 435-457.
10 王琳, 牛爱军. 骨代谢标志物在多发性骨髓瘤诊治中的应用现状 [J]. 实用医药杂志, 2011, 28(9): 844-846.
11 Jagtap VR, Ganu JV, Nagane NS. BMD and serum intact osteocalcin in postmenopausal osteoporosis women [J]. Indian J Clin Biochem, 2011, 26(1): 70-73.
12 Suriyachand K, Eamwijit T, Paisooksantivatana K, et al. A study of correlation of osteoblasts from peripheral blood with related bone turnover markers [J]. J Med Assoc Thai, 2011, 94(Suppl 5): S71-S75.
13 边平达, 应奇峰, 李秀央, 等. 80岁以上高龄老人骨密度与BTMS的相关性研究 [J]. 中华内分泌代谢杂志, 2014, 30(3): 206-209.
14 Krege JH, Lane NE, Harris JM, et al. PINP as a biological response marker during teriparatide treatment for osteoporosis [J]. Osteoporos Int, 2014, 25(9): 2159-2171.
15 Koivula MK, Risteli L, Risteli J. Measurement of aminoterminal propeptide of type I procollagen (PINP) in serum [J]. Clin Biochem, 2012, 45(12): 920-927.
16 Bunyaratavej N. Estimation of osteoblastic functions by biological bone markers [J]. J Med Assoc Thai, 2015, 98(Suppl 8): S5-S7.
17 Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density [J]. Cell, 1997, 89(2): 309-319.
18 廖二元, 曹旭. 湘雅代谢性骨病学 [M] . 北京: 科学出版社, 2013: 292-293.
19 Alatalo SL, Ivaska KK, Waguespack SG, et al. Osteoclast-derived serum tartrate-resistant acid phosphatsse 5b in Albors-Schouberg disease (typeⅡautesomat dominant osteopetrosis) [J]. Clin Chem, 2004, 50(5): 883-890.
20 Fledelius C, Johnsen AH, Cloos PA, et al. Characterization of urinary degradation products derived from type I collagen. Identification of a beta-isomerized Asp-Gly sequence within the C-terminal telopeptide (alpha1) region [J]. J Biol Chem, 1997, 272(15): 9755-9763.
21 Iwamoto J, Takeda T, Sato Y, et al. Comparison of the effect of alendronate on lumbar bone mineral density and bone turnover in men and postmenopausal women with osteoporosis [J]. Clin Rheumatol, 2007, 26(2): 161-167.
22 贾成瑶, 李萍. 尿吡啶啉和脱氧吡啶啉是骨吸收特异性生化标志物 [J]. 中国临床康复, 2002, 6(15): 2256-2257.
23 Ardawi MS, Maimani AA, Bahksh TA, et al. Reference intervals of biochemical bone turnover markers for Saudi Arabian women: a cross-sectional study [J]. Bone, 2010, 47(4): 804-814.
24 Qvist p, Christgau S, Pedersen BJ, et a1.Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status,posture, daylight, serum cortisol, and fasting [J]. Bone, 2002, 31(1): 57-61.
25 朱汉民. 加强骨转换生化标志物的检测和临床应用 [J]. 华中医学杂志, 2008, 32(1): 1-2.
26 王鸿度, 陈庄, 扶世杰, 等. 骨转换生化标志物昼夜节律的研究进展 [J]. 中国骨质疏松杂志, 2009, 15(12): 944-948, 943.
27 周学瀛, 夏维波. 骨转换生化标志物 [J]. 基础医学与临床, 2007, 27(10): 1093-1100.
28 彭应梅, 张雪竹, 于建春, 等. 骨转换生化指标的研究进展及选择依据 [J]. 现代生物医学进展, 2008, 8(3): 593-596.
29 薛延. 老年骨质疏松患者骨代谢标志物的检测与应用 [J]. 中华老年医学杂志, 2006, 25(6): 410-413.
30 Farr JN, Khosla S, Miyabara Y, et al. Effects of estrogen with micronized progesterone on cortical and trabecular bone mass and microstructure in recently postmenopausal women [J]. J Clin Endocrinol Metab, 2013, 98(2): E249-E257.
31 张萌萌. 中国老年学学会骨质疏松委员会骨代谢生化指标临床应用专家共识 [J]. 中国骨质疏松杂志, 2014, 20(11): 1263-1272.
32 邢学武, 向川, 卫小春. 骨转换生化标志物及其应用研究进展 [J]. 中国骨质疏松杂志, 2009, 15(8): 610-617.
33 Meier C, Nguyen TV, Center JR, et al. Bone resorption and osteoporotic fractures in elderly men: the dubbo osteoporosis epidemiology study [J]. J Bone Miner Res, 2005, 20(4): 579-587.
34 Marques EA, Gudnason V, Sigurdsson G, et al. Are bone turnover markers associated with volumetric bone density, size, and strength in older men and women? The AGES-Reykjavik study [J]. Osteoporos Int, 2016, 27(5): 1765-1776.
35 吴博, 戴如春. 骨质疏松骨折基础和临床研究方法进展 [J]. 国际内分泌代谢杂志, 2013, 33(2): 135-138.
36 Aktas B, Kasimir-Bauer S, Lehmann N, et al. Validity of bone marker measurements for monitoring response to bisphosphonate therapy with zoledronic acid in metastatic breast cancer [J]. Oncol Rep, 2013, 30(1): 441-447.
37 骨转换标志物助力骨质疏松症疗效监测 [J]. 中国骨质疏松杂志, 2013, 19(8): 874-875.
38 Vasikaran S, Cooper C, Eastell R, et al. International osteoporosis foundation and international federation of clinical chemistry and laboratory medicine position on bone marker standards in osteoporosis [J]. Clin Chem Lab Med, 2011, 49(8): 1271-1274.
39 Bandeira F, Costa AG, Soares Filho MA, et al. Bone markers and osteoporosis therapy [J]. Arq Bras Endocrinol Metabol, 2014, 58(5): 504-513.
40 Han B, Copeland M, Geiser AG, et al. Development of a highly sensitive, high-throughput, mass spectrometry-based assay for rat procollagen type-I N-terminal propeptide (PINP) to measure bone formation activity [J]. J Proteome Res, 2007, 6(11): 4218-4229.
41 Vasikaran S, Eastell R, Bruyere O, et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards [J]. Osteoporos Int, 2011, 22(2): 391-420.
42 Li M, Li Y, Deng W, et al. Chinese bone turnover marker study: reference ranges for C-terminal telopeptide of type I collagen and procollagen I N-terminal peptide by age and gender [J]. PLoS One, 2014, 9(8): 103841.
43 刘媛, 王永福, 刘忠厚, 等. 骨质疏松治疗的直接目标 [J]. 中国骨质疏松杂志, 2015, 21(3): 249-252.